Table 1 Permanent Pacemaker Subject Characteristics

Age (years)

81.6 ± 9.7

73.4 ± 12.9

< 0.001

Sex (% Women)

54.7

42.6

0.04

Number of Leads

0.75

Single

4.7

3.4

-

Dual

83.6

82.9

-

Biventricular

11.7

13.7

-

Atrial Fibrillation Burden (% of time)

16.0

9.3

0.05

Co-Morbidities

Hypertension (%)

81.3

73.0

0.11

Dyslipidemia (%)

74.2

67.6

0.22

Ischemic Heart Disease (%)

48.4

40.2

0.17

Mitral Regurgitation (% moderate or greater)

12.8

6.7

0.07

History of Atrial Fibrillation (%)

56.3

50.0

0.31

LBBB (%)

16.2

16.4

1.00

LVEF < 35% (%)

3.9

2.5

0.52

Diabetes (%)

29.7

28.4

0.81

Creatinine Clearance < 60 mL/min (%)

53.9

42.2

0.04

Smoking (% current)

5.5

3.9

0.59

Medications

Aspirin (%)

47.7

55.0

0.21

Beta Blockers (%)

69.5

68.3

0.90

Calcium Channel Blockers (%)

26.6

19.8

0.13

ACE Inhibitors (%)

21.1

26.7

0.29

Angiotensin II Receptor Blockers (%)

19.5

25.2

0.43

Angiotensin Receptor/Neprolysin Inhibitor (%)

0.8

1.5

1.00

Nitrates (%)

13.3

14.4

0.87

HMG-CoA Reductase Inhibitor (%)

64.8

64.9

1.00

Amiodarone (%)

7.8

7.9

1.00

Dofetilide (%)

2.4

1.0

0.38

Sotalol (%)

1.6

3.5

0.49

Class I Antiarrhythmics (%)

1.6

2.0

1.00

NOAC (%)

30.5

25.7

0.38

Warfarin (%)

28.1

23.8

0.44